<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:GLPG (Belgium) Also Trade In: Austria Belgium Germany Netherlands UK

Galapagos NV $ 161.72 5.61 (3.59%)

Volume:
64,893
Avg Vol (1m):
176,786
Market Cap $:
10.01 Bil
Enterprise Value $:
8.78 Bil
P/E (TTM):
0.00
P/B:
7.04
Warning! GuruFocus has detected 1 Severe warning sign with GLPG. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for GLPG (Galapagos NV) from 2015 to Oct 15 2019. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Galapagos NV stock (GLPG) PE ratio as of Oct 15 2019 is 0. More Details

Galapagos NV PE Ratio (TTM) Chart

EMBED

Galapagos NV PE Ratio (TTM) Historical Data

Total 1246
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Galapagos NV PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2019-10-150.0 2019-08-130.0
2019-10-140.0 2019-08-120.0
2019-10-110.0 2019-08-090.0
2019-10-100.0 2019-08-080.0
2019-10-090.0 2019-08-070.0
2019-10-080.0 2019-08-060.0
2019-10-070.0 2019-08-050.0
2019-10-040.0 2019-08-020.0
2019-10-030.0 2019-08-010.0
2019-10-020.0 2019-07-310.0
2019-10-010.0 2019-07-300.0
2019-09-300.0 2019-07-290.0
2019-09-270.0 2019-07-260.0
2019-09-260.0 2019-07-250.0
2019-09-250.0 2019-07-240.0
2019-09-240.0 2019-07-230.0
2019-09-230.0 2019-07-220.0
2019-09-200.0 2019-07-190.0
2019-09-190.0 2019-07-180.0
2019-09-180.0 2019-07-170.0
2019-09-170.0 2019-07-160.0
2019-09-160.0 2019-07-150.0
2019-09-130.0 2019-07-120.0
2019-09-120.0 2019-07-110.0
2019-09-110.0 2019-07-100.0
2019-09-100.0 2019-07-090.0
2019-09-090.0 2019-07-080.0
2019-09-060.0 2019-07-050.0
2019-09-050.0 2019-07-040.0
2019-09-040.0 2019-07-030.0
2019-09-030.0 2019-07-020.0
2019-09-020.0 2019-07-010.0
2019-08-300.0 2019-06-280.0
2019-08-290.0 2019-06-270.0
2019-08-280.0 2019-06-260.0
2019-08-270.0 2019-06-250.0
2019-08-260.0 2019-06-240.0
2019-08-230.0 2019-06-210.0
2019-08-220.0 2019-06-200.0
2019-08-210.0 2019-06-190.0
2019-08-200.0 2019-06-180.0
2019-08-190.0 2019-06-170.0
2019-08-160.0 2019-06-140.0
2019-08-150.0 2019-06-130.0
2019-08-140.0 2019-06-120.0

Galapagos NV PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Biotechnology » Biotechnology
Address Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.